

Edgar Filing: NOVAMED INC - Form 10KSB

NOVAMED INC  
Form 10KSB  
April 16, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-KSB

(Mark One)

Annual report under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2001.

Transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934 (No fee required) for the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission file number:000-26927

NOVAMED, INC

(Name of Small Business Issuer in Its Charter)

Nevada

58-2027283

(State or Other Jurisdiction of  
Incorporation or Organization)

(I.R.S. Employer  
Identification No.)

1403 East 900 South, Salt Lake City, Utah 84105

(Address of Principal Executive Offices) (Zip Code)

(801) 582-9609

(Issuer's Telephone Number, Including Area Code)

Securities registered under Section 12(b) of the Exchange Act:

Title of Each Class	Name of each Exchange on Which Registered
Common Stock (\$0.001 Par Value)	None

Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes X No

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and if no disclosure will be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB [ ].

The issuer's net sales for the year ended December 31, 2001, were \$0.

The aggregate market value of the registrant's common stock, \$0.001 par value (the only class of voting stock), held by non-affiliates was approximately \$155,314 based on the average closing bid and asked prices for the common stock on April 15, 2002.

At April 15, 2002, the number of shares outstanding of the registrant's common

# Edgar Filing: NOVAMED INC - Form 10KSB

stock, \$0.001 par value (the only class of voting stock), was 43,486,464.

## TABLE OF CONTENTS

	PAGE
PART I	
Item 1.	Description of Business.....1
Item 2.	Description of Property.....7
Item 3.	Legal Proceedings.....7
Item 4.	Submission of Matters to a Vote of Security-Holders.....7
PART II	
Item 5.	Market for Common Equity and Related Stockholder Matters.....7
Item 6.	Management's Discussion and Analysis or Plan of Operation....8
Item 7.	Financial Statements.....10
Item 8.	Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.....11
PART III	
Item 9.	Directors and Executive Officer.....11
Item 10.	Executive Compensation.....12
Item 11.	Security Ownership of Certain Beneficial Owners and Management.....12
Item 12.	Certain Relationships and Related Transactions.....13
Item 13.	Exhibits, List and Reports on Form 8-K.....14
	Signatures .....15

## PART I

This Report contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainty, including without limitation, the ability of the Company to continue its expansion strategy,

## Edgar Filing: NOVAMED INC - Form 10KSB

changes in costs of raw materials, labor, and employee benefits, as well as general market conditions, competition and pricing. Although the Company believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this Annual Report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

### ITEM 1. DESCRIPTION OF BUSINESS

#### A. Corporate Organization.

As used herein the term Company refers to NovaMed, Inc., its subsidiaries and predecessors, unless the context indicates otherwise. NovaMed, Inc. was incorporated in Nevada on November 26, 1996, as Conceptual Technologies, Inc. On April 9, 1998, the Company changed its name to reflect the acquisition of the operating subsidiaries of NovaMed Medical Products Incorporated (NMMP), and the resultant operational focus to the development, manufacture, and sale of mammary prosthesis devices. The Company acquired the operating subsidiaries of NMMP, pursuant to a Stock Purchase and Sale agreement dated February 25, 1998. NMMP was formed as a Nevada corporation in October of 1994 with the intent of producing a breast implant that would provide a safe and credible alternative to silicone gel filled implants. All of the outstanding shares of the three NMMP subsidiaries, NovaMed Medical Products Manufacturing Inc., NovaMedical Products GmbH and NovaMed Medical Supplies Corporation were acquired for 6,301,558 shares of the Company's common stock.

The Company is a medical device holding company that developed, manufactured, and marketed hydrogel and saline filled breast implant products that were used in primary augmentations, revisions, or reconstructive procedures. The Company through the period ended December 31, 2000, derived substantially all of its sales revenue from the sale of prosthesis products outside of North America.

#### B. Corporate History.

On December 11, 2000, the Medical Device Agency ("MDA") of the British Department of Health issued a device alert in connection with the recall of the Company's NOVAGOLD(TM) breast implant product. The decision to issue a device alert was made after discussions with the Company's subsidiary, Novamedical Products GmbH, which voluntarily agreed to suspend any further shipment or sale of the NOVAGOLD(TM) product in Britain until such time as the MDA was satisfied that the Company had completed an "adequate" biological safety assessment of the Company's hydrogel filling material. The device alert did not advise that the NOVAGOLD(TM) breast implant was unsafe, rather the MDA's position was that the Company did not satisfy the European device regulations for selling breast implants.

1

Concurrent with the MDA device alert, which was relevant only to sales in Britain, the Company was in the process of re-certifying its approval to sell the NOVAGOLD(TM) product throughout the European Union. Permission to sell throughout the European Union requires a CE Mark awarded by a notified body from one of the member nations. Notified bodies are certified by government health

## Edgar Filing: NOVAMED INC - Form 10KSB

authorities and given the responsibility of examining products for safety and efficacy before allowing sales within the European Union. Once the device alert was issued in Britain, the MDA's justifications for issuing the alert were published throughout the European Union. The ECM (the Company's notified body certified by the German government) learned of the MDA's device alert and decided not to re-certify the NOVAGOLD(TM) product for sale in the European Union until such time as the Company provided new testing data and a new CE Mark application to support the contention that the product was safe. Further, the ECM advised the Company to discontinue its sale of the NOVAGOLD(TM) until such time as a new CE Mark was obtained. The loss of the CE mark on the NOVAGOLD(TM) breast implant precluded the Company from generating any significant sales revenues.

The Company also submitted a Investigational Device Exemption (IDE) application to the Food and Drug Administration ("FDA") on January 9, 1999 for the purpose of obtaining permission from the FDA to start a clinical trial of the NOVAGOLD(TM) breast implant in the United States. The FDA responded on February 11, 1999 with certain deficiencies related to the IDE submission that required a Company response. The Company resubmitted its NOVAGOLD(TM) IDE submission on March 28, 2000 with responses to the FDA's noted deficiencies and additional information pertaining to the NOVAGOLD(TM). The Company's application for an IDE has been abandoned.

### C. Relocation and Closing of Operating Facilities.

The Company decided to relocate and consolidate its German operating facilities to the Company's headquarters in Minneapolis, Minnesota in December 2000. The decision was made due to the lack of substantial revenues at year end from sales in Europe with an indefinite prospect of future revenues coupled with the expense of operating two manufacturing facilities in two separate countries. The MDA device alert, and the Company's inability to re-certify the CE Mark for the NOVAGOLD(TM) breast implant product were added factors crucial to the decision. Management agreed that in order to increase manufacturing efficiencies and faithfully address quality control issues that a consolidation of all activities in Minneapolis would be in the best interests of the Company. The Company then devoted its limited resources on improving its facilities at 623 Hoover Street, Minneapolis, Minnesota. Despite efforts to fund operations, the Company was evicted from the premises located in Minneapolis on November 21, 2001 due to non-payment of rent.

### D. Disposition of German Subsidiary.

The decision to consolidate the Company's business to Minneapolis, Minnesota necessarily caused the disposition of Novamedical Products GmbH. Further to a Stock Purchase and Sales Agreement ("Sales Agreement") effective December 31, 2000, the Company sold its 100% ownership in Novamedical Products GmbH to Dr. Aydin Dogan. The sale involved the disposition of all the assets and liabilities of Novamedical Products GmbH with certain exceptions to Dr. Dogan in exchange for one million three hundred fifty thousand (1,350,000) shares of its common stock issued to Dr. Dogan and certain individuals or entities for the sole purpose of satisfying the outstanding third party liabilities of Novamedical Products GmbH. All assets excepted under the Sales Agreement were shipped to NovaMed's Minneapolis facility subsequent to December 31, 2000.

2

### E. Technology License Agreement.

## Edgar Filing: NOVAMED INC - Form 10KSB

During March 1, 1998, the Company entered into a License Agreement with AAB Corp and Greaco II, Ltd. ("Inventors") for the right to use certain patented technology in the production of the NOVAGOLD(TM) and NOVASALINE(TM) products. The term of the license was perpetual and permitted the use of the technology on an exclusive basis worldwide. The terms of the License Agreement caused the Company to pay a royalty equal to 5% of net revenue on sales of the products. A minimum royalty payment of \$21,000 was made every six month period with additional royalties, if warranted based on sales, made payable at the beginning of each month subsequent to the royalty period. On September 1, 2000, the Company failed to make a minimum royalty payment of \$21,000 and placed by the Inventors into default.

On December 29, 2000, the Company entered into a new License Agreement with the Inventors that once again enabled the Company to use certain patented technology in the production of the NOVAGOLD(TM) and NOVASALINE(TM) products. The license is perpetual and permits the use of the technology on an exclusive worldwide basis. The terms of the License Agreement cause the Company to pay a royalty equal to 7.5% of net revenue on sales of the products. A minimum royalty payment of \$21,000 was to be made every six month period with additional royalties, if warranted based on sales, made payable at the beginning of each month subsequent to the royalty period. The first minimum royalty payment of \$21,000 was to be made on May 1, 2001. The Company has failed to make any payments under the terms of the License Agreement and on August 21, 2001 the Inventors placed the Company in default of the License Agreement.

The Company entered into an Agreement for the Issuance, Sale and Purchase of Commons Stock with AAB Corp. and Greaco II, Ltd. ("Issuance Agreement") on December 29, 2000 as an inducement to have the Inventors enter into a new License Agreement, to settle obligations stemming from the March 1998 License Agreement and to provide a pre-payment of royalties due until May 1, 2001 under the December 29, 2000 Licence Agreement.

### F. Operations.

The Company was not able to generate any revenues in 2001. As of December 31, 2001 the Company had ceased attempts to resolve the MDA device alert and renew the CE Mark application. The Company is considering the viability of continuing in the business of developing, manufacturing and marketing breast implant products.

### G. Selection of a Business.

The Company considering the viability of its breast implant business and also is considering other business opportunities either through merger or acquisition that might create value for our shareholders. We have no day-to-day operations at the present time. Our sole officer and director devotes limited time and attention to the affairs of the Company. Management has adopted a conservative policy of seeking opportunities that they consider to be of exceptional quality. As a result of that policy the Company may have to wait some time before consummating a suitable transaction. Management recognizes that the higher the standards it imposes upon itself, the greater may be it's competitive disadvantages when vying with other acquiring interests or entities.

The Company does not intend to restrict its consideration to any particular

## Edgar Filing: NOVAMED INC - Form 10KSB

business or industry segment, and the Company may consider, among others, finance, brokerage, insurance, transportation, communications, research and development, service, natural resources, manufacturing or high-technology. However, due to the Company's limited financial resources, the scope and number of suitable candidate business ventures available is limited, and most likely the Company will not be able to participate in more than a single business venture. Accordingly, it is anticipated that the Company will not be able to diversify, but may be limited to one merger or acquisition. This lack of diversification will not permit the Company to offset potential losses from one business opportunity against profits from another.

The decision to participate in a specific business opportunity will be made upon management's analysis of the quality of the other firm's management and personnel, the anticipated acceptability of new products or marketing concepts, the merit of technological changes and numerous other factors which are difficult, if not impossible, to analyze through the application of any objective criteria. In many instances, it is anticipated that the historical operations of a specific venture may not necessarily be indicative of the potential for the future because of the necessity to substantially shift a marketing approach, expand operations, change product emphasis, change or substantially augment management, or make other changes. The Company will be dependent upon the management of a business opportunity to identify such problems and to implement, or be primarily responsible for the implementation of, required changes. Since the Company may participate in a business opportunity with a newly organized business or with a business which is entering a new phase of growth, it should be emphasized that the Company may incur risk due to the failure of the target's management to have proven its abilities or effectiveness, or the failure to establish a market for the target's products or services, or the failure to realize profits.

While the Company does not intend to rule out its consideration of any particular business or industry segment, management has determined to focus its principal interest in evaluating development stage companies in the electronic commerce, high-technology, communication technologies, information services and Internet industry segments.

We will not acquire or merge with any company for which audited financial statements cannot be obtained. It may be anticipated that any opportunity in which the Company participates will present certain risks. Many of these risks cannot be adequately identified prior to selection of the specific opportunity, and the Company's shareholders must, therefore, depend on the ability of management to identify and evaluate such risk. In the case of some of the opportunities available to the Company, it may be anticipated that the founders thereof have been unable to develop a going concern or that such business is in its development stage in that it has not generated significant revenues from its principal business activities prior to the Company's participation.

### H. Acquisition of Business.

In implementing a structure for a particular business acquisition, the Company may become a party to a merger, consolidation, reorganization, joint venture, franchise or licensing agreement with another corporation or entity. It may also purchase stock or assets of an existing business. On the consummation of a transaction, it is possible that the present management and shareholders of the Company will not be in control of the Company. In addition, the Company's sole officer and director may, as part of the terms of the acquisition transaction, resign and be replaced by new officers and directors without a vote of the Company's shareholders.

## Edgar Filing: NOVAMED INC - Form 10KSB

It is anticipated that any securities issued in any such reorganization would be issued in reliance on exemptions from registration under applicable federal and state securities laws. In some circumstances, however, as a negotiated element of this transaction, the Company may agree to register such securities either at the time the transaction is consummated, under certain conditions, or at a specified time thereafter. The issuance of substantial additional securities and their potential sale into any trading market may have a depressive effect on such market.

While the actual terms of a transaction to which the Company may be a party cannot be predicted, it may be expected that the parties to the business transaction will find it desirable to avoid the creation of a taxable event and thereby structure the acquisition in a so called "tax-free" reorganization under Section 368(a)(1) of the Internal Revenue Code of 1986, as amended (the "Code"). In order to obtain tax-free treatment under the Code, it may be necessary for the owners of the acquired business to own 80% or more of the voting stock of the surviving entity. In such event, the shareholders of the Company would retain less than 20% of the issued and outstanding shares of the surviving entity, which could result in significant dilution in the equity of such shareholders.

As part of our investigation, officers and directors of the Company will meet personally with management and key personnel, may visit and inspect material facilities, obtain independent analysis or verification of certain information provided, check reference of management and key personnel, and take other reasonable investigative measures, to the extent of the Company's limited financial resources and management expertise.

The manner in which each Company participates in an opportunity will depend on the nature of the opportunity, the respective needs and desires of the Company and other parties, the management of the opportunity, and the relative negotiating strength of the Company and such other management. With respect to any mergers or acquisitions, negotiations with target company management will be expected to focus on the percentage of the Company that target company shareholders would acquire in exchange for their shareholdings in the target company. Depending upon, among other things, the target company's assets and liabilities, the Company's shareholders will in all likelihood hold a lesser percentage ownership interest in the Company following any merger or acquisition. The percentage ownership may be subject to significant reduction in the event the Company acquires a target company with substantial assets. Any merger or acquisition effected by the Company can be expected to have a significant dilutive effect on the percentage of shares held by the Company's then shareholders.

### I. Operation of Business After Acquisition.

The Company's operation following its merger or acquisition of a business will be dependent on the nature of the business and the interest acquired. The Company is unable to determine at this time whether the Company will be in control of the business or whether present management will be in control of the Company following the acquisition. It may be expected that the business will present various challenges that cannot be predicted at the present time.

## Edgar Filing: NOVAMED INC - Form 10KSB

### J. Government Regulation.

The Company cannot anticipate the government regulations, if any, to which the Company may be subject until it has acquired an interest in a business. The use of assets to conduct a business that the Company may acquire could subject it to environmental, public health and safety, land use, trade, or other governmental regulations and state or local taxation. In selecting a business in which to acquire an interest, management will endeavor to ascertain, to the extent of the limited resources of the Company, the effects of such government regulation on the prospective business of the Company. In certain circumstances, however, such as the acquisition of an interest in a new or start-up business activity, it may not be possible to predict with any degree of accuracy the impact of government regulation. The inability to ascertain the effect of government regulation on a prospective business activity will make the acquisition of an interest in such business a higher risk.

### K. Competition.

The Company will be involved in intense competition with other business entities, many of which will have a competitive edge over the Company by virtue of their stronger financial resources and prior experience in business. There is no assurance that the Company will be successful in obtaining suitable business opportunities.

### L. Employees.

The Company currently has no employees. Our executive officer devotes as much time to the affairs of the Company as he deems appropriate. Management of the Company expects to use consultants, attorneys, and accountants as necessary, and does not anticipate a need to engage any full-time employees as long as business needs are being identified and evaluated. The need for employees and their availability will be addressed in connection with a decision concerning whether or not to acquire or participate in a specific business venture.

### M. Reports to Security Holders.

The Company's annual report will contain audited financial statements. The Company is not required to deliver an annual report to security holders and will not voluntarily deliver a copy of the annual report to the security holders. The Company intends to file all of its required information with the Securities and Exchange Commission ("SEC").

The public may read and copy any materials that are filed by the Company with the SEC at the SEC's Public Reference Room at 450 Fifth Street, N.W., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The statements and forms filed by the Company with the SEC have also been filed electronically and are available for viewing or copy on the SEC maintained Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The Internet address for this site can be found at <http://www.sec.gov>.

6

## ITEM 2. DESCRIPTION OF PROPERTY

The Company was headquartered at 623 Hoover St. N.E., Minneapolis, Minnesota



## Edgar Filing: NOVAMED INC - Form 10KSB

55413 where it leases office and manufacturing space totaling 15,000 square feet. The Company leased these facilities for \$6,679 per month. The lease was subject to incremental increases and expires in January 2003. The Company was evicted from the premises on November 21, 2001 for non-payment of rent and currently occupies limited office space, for which it pays no rent, owned by the Company's president, at 1403 East 900 South, Salt Lake City, Utah 84105

The Company believes that its current office space is generally suitable and adequate to accommodate its current operations.

### ITEM 3. LEGAL PROCEEDINGS

The Company is currently not a party to any pending legal proceeding

### ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders during the period covered by this report.

## PART II

### ITEM 5. MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S COMMON EQUITY AND OTHER SHAREHOLDER MATTERS

The Company's common stock is traded on Over the Counter Bulletin Board under the symbol NVMD.OB.

The table below sets forth the high and low sales prices for the Company's common stock for each quarter of 2000 and 2001. The quotations below reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions:

Year	Quarter Ended	High	Low
	-----	----	---
2000	March 31	\$2.12	\$0.40
-----			
	June 30	\$1.31	\$0.27
	September 30	\$0.28	\$0.14
	December 31	\$0.25	\$0.02
2001	March 31	\$0.06	\$0.02
-----			
	June 30	\$0.05	\$0.01
	September	\$0.02	\$0.01
	December 31	\$0.03	\$0.01

#### A. Record Holders

As of April 15, 2002, there were approximately 330 shareholders of record holding a total of 43,486,464 shares of common stock. The holders of the common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Holders of the common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock.

## Edgar Filing: NOVAMED INC - Form 10KSB

### B. Dividends

The Company has not declared any cash dividends since inception and does not anticipate paying any dividends in the foreseeable future. The payment of dividends is within the discretion of the board of directors and will depend on the Company's earnings, capital requirements, financial condition, and other relevant factors. There are no restrictions that currently limit the Company's ability to pay dividends on its common stock other than those generally imposed by applicable state law.

### ITEM 6 MANAGEMENTS DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

#### General

The Company is a medical device holding company that developed, manufactured, and marketed hydrogel and saline filled breast implant products that were used in primary augmentations, revisions, or reconstructive procedures.

The Company manufactured and marketed two different pre-filled single lumen mammary prostheses (breast implants), the NOVAGOLD<sup>TM</sup> and the NOVASALINE<sup>TM</sup>. These products were designed to address the safety concerns associated with silicone gel-filled implants, as voiced by the FDA's decision in April of 1992 which mandated that silicone gel implants would thereafter only be available under controlled clinical studies. Both products were used for routine cosmetic breast augmentation and for breast reconstruction following either subcutaneous or modified radical mastectomy. The Company has realized no sales revenues during 2001, due to the prohibition placed on the sale of the Company's products and the default on the License Agreement related to the Company's use of patented technology in its products.

#### A. Results of Operations

##### Sales

Sales for the year ended December 31, 2001 decreased to \$ 0 from \$1,141,033 for the year ended December 31, 2000. The decrease in revenues is primarily attributable to the Company's failure to re-certify the NOVAGOLD<sup>TM</sup> product in the Europe which prohibited new sales in 2001.

International sales accounted for 100% of total net sales in 2000. The absence of sales in 2001 is directly related to the MDA's device alert for the NOVAGOLD<sup>TM</sup> product and the advice of the Company's notified body that all further shipment of the NOVAGOLD<sup>TM</sup> product be suspended. Sales of the NOVAGOLD<sup>TM</sup> breast implant accounted for over 98% of all Company revenues in 2000.

8

##### Losses

The net loss for the year ended December 31, 2001 was \$475,564 as compared to a loss of \$1,500,351 for the year ended December 31, 2000, which is a decrease in losses of \$1,024,787. The decrease was attributable primarily to the suspension of product sales in Europe and the default on the License Agreement which terminated the Company's right to its products. The effect of these events resulted in limited operations through 2001 causing a decrease in costs.

## Edgar Filing: NOVAMED INC - Form 10KSB

The Company expects to incur losses through fiscal 2002 and there can be no assurance that the Company will establish a profitable revenue stream until such time as a new business opportunity is adopted through merger or acquisition.

Selling, general and administrative expenses for the year ended December 31, 2001, decreased to \$566,959 from \$1,681,128 for the year ended December 31, 2000, a decrease of \$1,114,169. The decrease in selling general and administrative expenses resulted from limited operations through the period.

The Company was obligated to pay a royalty equal to 5% of net revenue of the product. A minimum royalty payment of \$21,000 is made for each six month period. Royalty expense for the year ended December 31, 2001 and 2000 was approximately \$42,000 and \$53,000, respectively. The Company did not make royalty payments under the License Agreement and therefore lost all rights to continue the sale of its products.

Depreciation and amortization expenses for the years ended December 31, 2000 and December 31, 1999 were \$17,924 and \$40,327 respectively.

### Cost of Sales

The largest factors in the variation from year to year in the cost of sales as a percentage of net sales were the cost of raw materials and the yield of finished goods from the Company's manufacturing facilities.

The cost of sales for the year ended December 31, 2001 was \$0 compared to \$812,870 for the year ended December 31, 2000. The decrease was attributable primarily to the suspension of product sales in Europe and the default on the License Agreement which terminated the Company's right to its products. The effect of these events resulted in limited operations through 2001 causing a decrease in cost of sales.

### B. Income Tax Expense (Benefit)

The Company has an income tax benefit resulting from net operating losses to offset any operating profit.

### C. Impact of Inflation

The Company believes that inflation has had a negligible effect on operations over the past three years.

### D. Liquidity and Capital Resources

The Company has expended significant resources on research and development in the past. The Company does not expect to expend any sum on research or development.

Cash flow used in operations was \$211,745 for the year ended December 31, 2001, as compared to cash flow used in operations of \$137,229 for the year ended December 31, 2000. Negative cash flows from operating activities for the year ended December 31, 2001 are primarily attributable to losses from operations.

## Edgar Filing: NOVAMED INC - Form 10KSB

Cash flow generated from financing activities was \$200,000 for the year ended December 31, 2001 and \$173,990 for the year ended December 31, 2000. The Company issued convertible debentures in the amount of \$25,000 each through the period ended December 31, 2001. The debentures were subsequently assigned to a third party in connection with the sale of a former subsidiary.

The Company has funded its cash needs from inception through December 31, 2001 through revenues and a series of debt and equity transactions, including several private placements. The bulk of these transactions have taken place outside the United States. Since there is currently no revenue stream, the Company expects that it will require new debt or equity transactions to satisfy cash needs over the next twelve months.

### E. Capital Expenditures

The Company made no significant capital expenditures on property or equipment for the year ended December 31, 2001 and expenditures of approximately \$41,000 for the year ended December 31, 2000.

### F. Going Concern

The Company's auditors have expressed an opinion as to the Company's ability to continue as a going concern as a result of an accumulated deficit of \$6,440,940 as of December 31, 2001. The Company's ability to continue as a going concern is subject to the ability of the Company to obtain a profit and /or obtaining the necessary funding from outside sources. Management's plan to address the Company's ability to continue as a going concern, includes: (1) obtaining funding from private placement sources; (2) obtaining additional funding from the sale of the Company's securities; (3) establishing revenues from a suitable business opportunity; (4) obtaining loans and grants from various financial institutions where possible. Although management believes that it will be able to obtain the necessary funding to allow the Company to remain a going concern through the methods discussed above, there can be no assurances that such methods will prove successful.

## ITEM 7. FINANCIAL STATEMENTS

The Company's financial statements for the fiscal year ended December 31, 2001 are attached hereto as pages F-1 through F-21.

Edgar Filing: NOVAMED INC - Form 10KSB

Consolidated balance sheet	F-3
Consolidated statement of operations	F-4
Consolidated statement of stockholders' equity	F-5
Consolidated statement of cash flows	F-6
Notes to consolidated financial statements	F-7

-----  
F-1

INDEPENDENT AUDITORS' REPORT

To the Board of Directors  
and Stockholders of  
NovaMed, Inc.

We have audited the accompanying consolidated balance sheet of NovaMed, Inc., as of December 31, 2001, and the related consolidated statements of operations, stockholders' deficit, and cash flows for the two years then ended. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present

## Edgar Filing: NOVAMED INC - Form 10KSB

fairly, in all material respects, the consolidated financial position of NovaMed, Inc., as of December 31, 2001, and the results of their consolidated operations and their cash flows for the two years then ended, in conformity with accounting principles generally accepted in the United States.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has a working capital deficit, an accumulated deficit and has incurred losses since inception. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters also are described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

TANNER + CO  
Salt Lake City, Utah  
April 10, 2002

F-2

NOVAMED, INC.  
Consolidated Balance Sheet  
December 31

	2001
Assets	
Current assets:	
Cash	\$ 10,034
Note receivable	15,000
	-----
Total current assets	25,034
Property and equipment, net	33,071
	-----
	\$ 58,105
	-----
Liabilities and Stockholders' Deficit	
Current liabilities:	
Note payable	\$ 20,000
Accounts payable	142,953
Accrued royalties	42,000
Accrued liabilities	11,905
	-----
Total current liabilities	216,858

Edgar Filing: NOVAMED INC - Form 10KSB

Commitments and contingencies	-
Stockholders' deficit:	
Common stock, \$.001 par value, 50,000,000 shares authorized; 43,486,464 shares issued and outstanding	43,487
Additional paid-in capital	6,238,700
Accumulated deficit	(6,440,940)
	-----
Total stockholders' deficit	(158,753)
	-----
	\$ 58,105
	-----

See accompanying notes to consolidated financial statements.

F-3

NOVAMED, INC.  
Consolidated Statement of Operations  
Years Ended December 31,

	2001	2000
	-----	-----
Net sales	\$ -	\$ 1,141,033
	-----	-----
Costs and expenses:		
Cost of sales	-	812,870
Selling, general and administrative	566,959	1,681,128
Research and development	-	45,320
Write down of inventory	129,204	125,000
	-----	-----
	696,163	2,664,318
	-----	-----
Loss from operations	(696,163)	(1,523,285)
Gain on sale of subsidiary	225,000	-
Other income	3,099	31,808
Interest expense	(7,500)	(8,874)
	-----	-----
Loss before income taxes	(475,564)	(1,500,351)
	-----	-----

Edgar Filing: NOVAMED INC - Form 10KSB

Benefit from income taxes	-	-
	-----	-----
Net loss	\$ (475,564)	\$ (1,500,351)
	-----	-----
Loss per common share-basic and diluted	\$ (\$01)	(.09)
	-----	-----
Weighted average common shares - basic and diluted	43,486,000	15,872,000
	-----	-----

See accompanying notes to consolidated financial statements.

F-4

NOVAMED, INC.  
Consolidated Statement of Stockholders' Equity  
Years Ended December 31, 2001 and 2000

	Common Shares	Stock Amount	Additional Paid-in Capital	Cumulative Foreign Currency Translation Adjustment	Stock Subscription Receivable	Accumulated Deficit
	-----	-----	-----	-----	-----	-----
Balance at January 1, 2000	15,196,464	15,197	5,170,635	1,208	(440,000)	(4,400,000)
Issue Common Stock for:						
Cash	320,000	320	143,680	-	-	-
Services	11,470,000	11,470	379,375	-	-	-
Sale of foreign subsidiary to related party	1,350,000	1,350	503,670	(1,208)	-	-
Settlement of accounts payable	6,400,000	6,400	217,600	-	-	-
Collection of stock subscription receivable	-	-	-	-	9,990	-
Stock subscription receivable	8,750,000	8,750	253,750	-	(262,500)	-
Net loss	-	-	-	-	-	(1,500,351)
	-----	-----	-----	-----	-----	-----
Balance at						



Edgar Filing: NOVAMED INC - Form 10KSB

December 31, 2000	43,486,464	43,487	6,668,710	\$	(692,510)	(5,9
Services exchanged for subscriptions receivable	-	-	-	-	262,500	
Write-off of subscription receivables	-	-	(430,010)	-	430,010	
Net Loss	-	-	-	-	-	(4
Balance at December 31,	43,486,464	\$ 43,487	\$6,238,700	\$	\$ -	\$ (6,4

See accompanying notes to consolidated financial statements.

F-5

NOVAMED, INC.  
Consolidated Statement of Cash Flows  
Years Ended December 31,

	2001	2000
Cash flows from operating activities:		
Net loss	\$ (475,564)	\$ (1,500,351)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation	17,924	40,327
Stock subscriptions satisfied for services	262,500	390,845
Gain on sale of subsidiary	(225,000)	-
Write down of inventory	129,204	125,000
(Increase) decrease in:		
Receivables	-	160,270
Inventories	-	502,589
Other assets	-	54,328
Increase (decrease) in:		
Cash overdraft	-	(16,736)
Accounts payable and accrued liabilities	79,191	106,499
Net cash used in operating activities	(211,745)	(137,229)
Cash flows from investing activities :		
Purchase of property and equipment	-	(41,219)
Proceeds from the sale of subsidiary	10,000	-

Edgar Filing: NOVAMED INC - Form 10KSB

	-----	-----
Net cash provided by (used in) investing activities	10,000	(41,219)
	-----	-----
Cash flows from financing activities:		
Proceeds from convertible debentures	200,000	-
Proceeds from note payable	-	20,000
Issuance of common stock	-	144,000
Collection of stock subscription receivable	-	9,990
	-----	-----
Net cash provided by financing activities	200,000	173,990
	-----	-----
Net decrease in cash	(1,745)	(4,458)
Cash, beginning of year	11,779	16,237
	-----	-----
Cash, end of year	\$ 10,034	\$ 11,779
	-----	-----

-----  
See accompanying notes to financial statements

F-6

NOVAMED, INC.  
Notes to Consolidated Financial Statements

December 31, 2001 and 2000

- 
1. Organization and Presentation    The consolidated financial statements consist of NovaMed, Inc. (formerly Conceptual Technologies, Inc.) and its wholly owned subsidiaries.

On December 31, 2000 the Company sold its wholly owned subsidiary Novamedical Products, GmbH and issued 1,350,000 shares of the Company's common stock to a significant shareholder and former officer in exchange for ten dollars and the assumption of all Novamedical Products, GmbH net liabilities. After the sale of Novamedical Products, GmbH the Company has had no foreign operations or sales.

The Company was engaged primarily in the development, manufacture and sale of mammary prostheses products. The flagship product is NOVAGOLD, a pre-filled hydrogel textured single lumen breast implant that utilizes a unique water based filling material that is designed to be biocompatible.

## Edgar Filing: NOVAMED INC - Form 10KSB

The ability of the Company to further sale, development, and manufacture this product is permanently impaired due to the Company's default on its Royalty Agreement for certain technology rights related to the development, manufacturing and sale of the pre-filled hydrogel textured single lumen breast, which rights have been terminated (See note 13).

Through the period ended December 31, 2000, the Company derived substantially all of its sales revenue from the sale of prosthesis products outside of North America. The Company has not yet obtained FDA approval for its product in the United States and must obtain that approval before domestic sales will be feasible.

Effectively On December 11, 2000, the Medical Device Agency ("MDA") of the British Department of Health issued a device alert in connection with the recall of the Company's NOVAGOLDTM breast implant product. The decision to issue a device alert was made after discussions with the Company's subsidiary, Novamedical Products GmbH, which voluntarily agreed to suspend any further shipment or sale of the NOVAGOLDTM product in Britain until such time as the MDA is satisfied that the Company has completed an "adequate" biological safety assessment of the Company's hydrogel filling material. The device alert did not advise that the NOVAGOLDTM breast implant was unsafe, rather the MDA's position is that the Company did not satisfy the European device regulations for selling breast implants.

-----  
F-7

NOVAMED, INC.  
Notes to Financial Statements  
Continued  
-----

1. Organization and Presentation Continued
- The MDA device alert stated that the MDA had not identified any definite risk associated with the NOVAGOLDTM implant and did not recommend explantation for the approximately 250 patients in Britain. The device alert further provided that there was no information to indicate that there were specific risks to women or their children, either during pregnancy or from breast feeding associated with the NOVAGOLDTM breast implant.

Concurrent with the MDA device alert, which was relevant only to sales in Britain, the Company was in the process of re-certifying its approval to sell the NOVAGOLDTM product throughout the European Union. Permission to sell throughout the European Union requires a CE Mark awarded by a notified body from one of the member nations. Notified bodies are certified by government health authorities and given the responsibility of examining products for safety and efficacy before allowing sales within the European Union. Once the

## Edgar Filing: NOVAMED INC - Form 10KSB

device alert was issued in Britain, the MDA's justifications for issuing the alert were published throughout the European Union. The ECM (the Company's notified body certified by the German government) learned of the MDA's device alert and decided not to re-certify the NOVAGOLDTM product for sale in the European Union until such time as the Company provided new testing data and a new CE Mark application to support the assertion that the product was safe. Further, the ECM advised the Company to discontinue its sale of the NOVAGOLDTM product until such time as a new CE Mark is obtained.

The loss of the CE Mark on the NOVAGOLDTM breast implant precludes the Company from generating any significant sales revenues until such time as the Company can be approved for a new CE Mark.

Due to the above-noted items, the Company was not able to generate any revenues in 2001. As of December 31, 2001 the Company had ceased attempts to resolve the MDA device alert and renew the CE Mark application. The Company is considering the viability of continuing in the business of development, manufacture and sale of mammary prostheses product.

---

F-8

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

---

2. Going Concern
- At December 31, 2001 the Company had a working capital deficit, an accumulated deficit and has incurred losses since inception as well as negative cash flow from operations. Further, the License Agreement has been terminated rendering the Company unable to use patented technology with its products. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company's ability to continue as a going concern is subject to the obtaining necessary funding from outside sources. The Company intends to begin seeking a potential merger partner and cash infusion through a reverse acquisition transaction. There can be no assurance that the Company will be successful in these efforts.

3. Significant Accounting Principles of Consolidation
- The consolidated financial statements include the accounts

## Edgar Filing: NOVAMED INC - Form 10KSB

Policies of the Company, and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

### Cash Equivalents

For purposes of the statement of cash flows, cash includes all cash and investments with original maturities to the Company of three months or less.

### Inventories

Inventories are recorded at the lower of cost or market, cost being determined on a first-in, first-out (FIFO) method. During the year ended December 31, 2001 the Company determined that \$129,204 its inventory was impaired based on the inability of the Company to sell its products and based on a default of license agreement ( See note 13).

### Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation. Depreciation and amortization on property and equipment is determined using the straight-line method over the estimated useful lives of the assets which is approximately 4 years. Expenditures for maintenance and repairs are expensed when incurred and betterments are capitalized. Gains and losses on sale of property and equipment are reflected in operations.

---

F-9

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

---

3. Significant Accounting Policies Continued Revenue Recognition Revenue is recognized when a valid purchase order has been received, product has been shipped, the selling price is fixed or determinable, and collectibility is reasonably assured.

### Income Taxes

Deferred taxes are computed using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are not recognized unless it is more likely than not that the asset will be realized in future years.

## Edgar Filing: NOVAMED INC - Form 10KSB

### Earnings Per Share

The computation of basic earnings per common share is based on the weighted average number of shares outstanding during each year.

The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents, which would arise from the exercise of stock options and warrants outstanding using the treasury stock method and the average market price per share during the year. Options to purchase 550,000 shares of common stock at \$1.30 per share were outstanding at December 31, 2000, but were not included in the diluted earnings per share calculation because their effect would have been antidilutive. There were no outstanding options as of December 31, 2001.

### Concentration of Credit Risk

Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of trade and note receivables. In the normal course of business, the Company provides on-going credit evaluations of its customers and maintains allowances for possible losses which, when realized, have been within the range of management's expectations.

F-10

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

3. Significant Accounting Policies Continued

#### Concentration of Credit Risk - Continued

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses in such account and believes it is not exposed to any significant credit risk on cash and cash equivalents.

#### Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

#### Reclassifications

Certain amounts in the 2000 financial statements have been reclassified to conform with the current year presentation.

Edgar Filing: NOVAMED INC - Form 10KSB

4. Note Receivable The Company has a note receivable of \$15,000 due from an individual, with interest at 6%, and due on or before July 2002.
5. Property and Equipment Property and equipment consist of the following:
- |                               |    |          |
|-------------------------------|----|----------|
| Equipment and fixtures        | \$ | 71,694   |
| Less accumulated depreciation |    | (38,623) |
|                               |    | -----    |
|                               | \$ | 33,071   |
|                               |    | -----    |
6. Note Payable The Company has a note payable of \$20,000 due to an entity which is unsecured, non-interest bearing, and due on demand.
7. Related Party Transactions The Company incurred consulting expenses of \$24,000 and \$67,000 to an Officer of the company for the years ended December 31, 2001 and 2000, respectively.

-----  
F-11

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued  
-----

7. Related Party Transactions Continued During the year ended December 31, 2000 the Company leased a facility from a shareholder. The lease required monthly payments of approximately \$8,000. Rent expense for the year ended December 31, 2000 was approximately \$80,000, respectively.
8. Income Taxes The provision for income taxes is different than amounts which would be provided by applying the statutory federal income tax rate to loss before the provision for income taxes for the following reasons:

	Years Ended December 31,	
	2001	2000
	-----	-----
Federal income tax benefit at statutory rate	\$ 161,000	\$ 510,000
Gain on sale of subsidiary	-	(163,000)
Change in valuation allowance	(161,000)	(347,000)
	-----	-----
	\$ -	\$ -

Edgar Filing: NOVAMED INC - Form 10KSB

-----  
Deferred tax assets (liabilities) are comprised of the following:

Net operating loss carryforward	\$	1,431,000
Impairment on Inventory		86,000
Valuation allowance		(1,517,000)
		-----
	\$	-
		-----

A valuation allowance has been established for the net deferred tax asset due to the uncertainty of the Company's ability to realize such asset.

At December 31, 2001, the Company has a net operating loss carryforward available to offset future taxable income of approximately \$4,208,000, which begins to expire in 2010. The amount of net operating loss carryforward that can be used in any one year will be limited by the applicable tax laws which are in effect at the time such carryforward can be utilized. The change in ownership of the Company may reduce the amount of loss allowable.

-----  
F-12

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued  
-----

9. Supplemental Cash Flow Information During the year ended December 31, 2001 the Company determined that \$430,010 of its stock subscriptions receivable were uncollectible and determined not to cancel the related issued shares. Accordingly \$430,000 has been off-set to additional paid-in-capital.

During the year ended December 31, 2001 the Company sold to an individual a wholly-owned subsidiary which was formed in 2001. The company had no cost basis in the subsidiary and sold the subsidiary for a gain of \$225,000 as follows:

Cash	\$	10,000
Note receivable		15,000
Assignment of convertible debentures		200,000



Edgar Filing: NOVAMED INC - Form 10KSB

	-----
Gain on sale of minority interest	\$ 225,000
	-----

On December 31, 2000 the Company sold its foreign wholly owned subsidiary, Novamedical Products GmbH, and issued 1,350,000 of the Company's common stock to a stockholder and former officer in exchange for ten dollars and assumption of all Novamedical Products GmbH net liabilities as follows:

Receivables	\$ (71,931)
Inventories	(1,075)
Property and equipment, net	(26,677)
Other assets	(4,980)
Cash overdraft	23,479
Payables	584,854
Issuance 1,350,000 Novamed, Inc. common shares	1,350
Foreign currency adjustment, net	(1,208)
	-----
Gain on sale to related party	\$ 503,812
	-----

During the year ended December 31, 2000 the Company issued 6,400,000 of its common shares for settlement of \$224,000 of accounts payable.

-----  
F-13

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

- 
9. Supplemental Cash Flow Information Continued      During the year ended December 31, 2000 the Company issued common stock for stock subscription receivables of \$262,500.
- During the years ended December 31, 2001 and 2000, the Company paid interest of \$800 and \$9,000, respectively. The Company did not pay any income taxes in 2001 or 2000.
10. Stock Options and Warrants      During the year ended December 31, 1999 the Company established a stock option plan (the Plan), which allowed a maximum of 1,315,000 options be granted to purchase common stock at prices generally not less than the fair market value of common stock at the date of grant. Under the Plan, grants of options may be made to selected officers,

## Edgar Filing: NOVAMED INC - Form 10KSB

employees and non-employees without regard to any performance measures. The options may be immediately exercisable or may vest over time as determined by the Board of Directors.

Information regarding the stock options and warrants is summarized below:

	Number of Options	Weighted Average Exercise Price
	-----	-----
Outstanding at January 1, 2000	500,000	\$1.30
Granted	370,000	.45
Exercised	(320,000)	.45
	-----	-----
Outstanding at December 31, 2000	550,000	1.22
Granted	-	
Expired	(550,000)	1.22
	-----	-----
Outstanding at December 31, 2001	\$	\$ -
	-----	-----

F-14

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

10. Stock Options and Warrants Continued
- The Company has adopted the disclosure only provisions of Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation." Accordingly, no compensation expense has been recognized for stock options granted to employees. Had compensation expense for the Company's stock options been determined based on the fair value at the grant date consistent with the provisions of SFAS No. 123, the Company's results of operations would have been reduced to the pro forma amounts indicated below:

	Years Ended December 31,	
	-----	-----
	2001	2000
	-----	-----
Net loss - as reported	\$ (475,564	\$ (1,500,351)

## Edgar Filing: NOVAMED INC - Form 10KSB

Net loss - pro forma	\$ (475,564	\$ (1,675,768)
Loss per share - as reported	\$ (. \$1)	(.09)
Loss per share - pro forma	\$ (. \$1)	(.11)
	-----	

The fair value of each option grant During the ended December 31, 2000 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:

Expected dividend yield	\$	-
Expected stock price volatility		381%
Risk-free interest rate		7%
Expected life of options		1 year
	-----	

The weighted average fair value of options granted during 2000, was \$.47

As of December 31, 2001, there were no options or warrants to purchase common stock outstanding.

F-15

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

- 
11. Gain On Sale Of Subsidiary      During the year ended December 31, 2001 the Company sold to an individual a wholly-owned subsidiary which was formed in 2001. The company had no cost basis in the subsidiary which it sold for a gain of \$225,000. In exchange for the subsidiary, the Company assigned \$200,000 of convertible debentures, received \$10,000 cash and obtained a note receivable for \$15,000 which bears interest at 6% and is due on or before July 1, 2002. The note receiveable was paid in February 2002.
12. Disposal of Subsidiary      On December 31, 2000, the Company sold its wholly owned foreign subsidiary Novamedical Products GmbH to an officer and shareholder of the Company. The Company realized a net contribution to its equity of \$503,812 from the sale by issuing 1,350,000 shares of the Company's common shares in exchange for the extinguishment of net liabilities of \$505,162.
13. Commitments and Contingencies      Royalty Agreement  
The Company had a license agreement which assigned the intellectual property, technology and patent rights used in and around manufacturing breast implants. The term of this license was perpetual and allowed for the worldwide exclusive rights to manufacture and market the product. As part of this agreement, the Company agreed to pay a royalty equal to 5% of net revenue of the product and a minimum

Edgar Filing: NOVAMED INC - Form 10KSB

royalty payment of \$21,000 for each six month period beginning May 1, 2001. During the year ended December 31, 2001 the Company was in default of the agreement from not remitting minimum royalty payments as required by the agreement and the Company's rights to the technology were terminated. The termination of these rights prohibits sales of the Company's traditional product which accounts for substantially all product sales in 2000 and preceding years. During the years ended December 31, 2001 and 2000, the Company had royalty expense relating to this agreement of approximately \$42,000 and \$53,000, respectively. At December 31, 2001 the Company had accrued royalty expense of \$42,000.

F-16

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

13. Commitments and Contingencies Continued

Operating Lease

The Company's wholly owned subsidiary NovaMed Medical Products Manufacturing, Inc., leased a facility under a non-cancelable operating lease which expires January 2004. Rental expense incurred under this lease for the years ended December 31, 2001 and 2000 totaled approximately \$80,000 and \$58,000, respectively. At December 31, 2001 the Company was in default of its lease payments and had been evicted from the facility. Under the lease obligation the Company may be liable for future minimum lease payments for the residue of the stated term less the fair rental value of the leased facility taking into account the time and expenses necessary for the lessor, to re-let the facility. Minimum lease payments for which the Company was obligated according to the agreement at December 31, 2001 for this operating lease is as follows:

Year	Amount
	-----
2002	\$ 62,000
2003	62,000
2004	5,200
	-----
Total future minimum lease payments	\$ 129,200
	-----

Operating Lease- Continued

At December 31, 2001 the Company had recorded a liability related to this lease of \$28,856 which is included in accounts payable.

Litigation

The Company may become or is subject to investigations, claims or lawsuits ensuing out of the conduct of its

Edgar Filing: NOVAMED INC - Form 10KSB

business, including those related to product safety and health, product liability, commercial transactions, etc. The Company is currently not aware of any such items which it believes could have a material adverse effect on its financial position.

---

F-17

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

---

14. Fair Value of Financial Instruments      The Company's financial instruments consist of cash, a note receivable, payables, and a notes payable. The carrying amount of cash, receivables and payables approximates fair value because of the short-term nature of these items. The aggregate carrying amount of the notes payable approximates fair value as the individual borrowings bear interest at market interest rates.
15. Recent Accounting Pronouncements      In August 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 144 "Accounting for the Impairment of Long-Lived Assets". This Statement addresses financial accounting and reporting for the impairment of long-lived assets and for long-lived assets to be disposed of. This Statement supercedes FASB Statement 121 and APB Opinion No. 30. This Statement retains certain fundamental provisions of Statement 121, namely; recognition and measurement of the impairment of long-lived assets to be held and used, and measurement of long-lived assets to be disposed of by sale. The Statement also retains the requirement of Opinion 30 to report discontinued operations separately from continuing operations. This Statement also amends ARB No. 51 to eliminate the exception of consolidation for a temporarily controlled subsidiary. The provisions of this statement are effective for financial statements issued for fiscal years beginning after December 15, 2001.

---

F-18

NOVAMED, INC.  
Notes to Consolidated Financial Statements  
Continued

---

Edgar Filing: NOVAMED INC - Form 10KSB

15. Recent Accounting Pronouncements Continued

In June 2001, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 143, "Accounting for Asset Retirement Obligations". This Statement addresses financial accounting and reporting for obligations associated with the retirement of tangible long-lived assets and the associated asset retirement costs. This Statement is effective for financial statements issued for fiscal years beginning after June 15, 2002. This Statement addresses financial accounting and reporting for the disposal of long-lived assets

Management does not expect the adoption of SFAS No. 144 or 143 to have a significant impact on the financial position or results of operations of the Company. In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141 "Business Combinations" (SFAS No. 141) and No. 142 "Goodwill and Other Intangibles" (SFAS No. 142). SFAS No. 141 and No. 142 are effective for the Company on July 1, 2001. SFAS No. 141 requires that the purchase method of accounting be used for all business combinations initiated after June 30, 2001. The statement also establishes specific criteria for recognition of intangible assets separately from goodwill and requires unallocated negative goodwill to be written off immediately as an extraordinary gain. SFAS No. 142 primarily addresses the accounting for goodwill and intangible assets subsequent to their acquisition. The statement requires that goodwill and indefinite lived intangible assets no longer be amortized and be tested for impairment at least annually. The amortization period of intangible assets with finite lives will no longer be limited to forty years. Management does not expect the adoption of SFAS No. 141 and 142 to have a significant impact on the financial position or results of operations of the Company.

SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities, was issued in September 2000. SFAS No. 140 is a replacement of SFAS No. 125, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities. Most of the provisions of SFAS No. 125 were carried forward to SFAS No. 140 without reconsideration by the Financial Accounting Standards Board (FASB), and some were changed only in minor ways. In issuing SFAS No. 140, the FASB included issues and decisions that had been addressed and determined since the original publication of SFAS No. 125. SFAS No. 140 is effective for transfers after March 31, 2001. Management does not expect the adoption of SFAS No. 140 to have a significant impact on the financial position or results of operations of the Company.

-----  
F-19

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

There were no changes in accountants or disagreements between the Company and its accountants.

# Edgar Filing: NOVAMED INC - Form 10KSB

## PART III

### ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS, AND CONTROL PERSONS

The officers and directors of the Company as of December 31, 2001 are as follows:

Name	Age	Position
Ruairidh Campbell	39	president and director

Ruairidh Campbell has lead the Company since his appointment as president in 1995. He estimates that he will spend approximately 20 percent of his time, approximately 10 hours per week, on the Company's business during the next 12 months. He also has significant responsibilities with other companies, as detailed in the following paragraph.

Mr. Campbell graduated from the University of Texas at Austin with a Bachelor of Arts in History and then from the University of Utah College of Law with a Juris Doctorate with an emphasis in corporate law, including securities and taxation. Over the past five years he has been an officer and director of several public companies: InvestNet, Inc., a company involved in exploration for precious metals in British Columbia, Canada from March 2000 to present, Allied Resources Inc., a Canadian based oil and gas development company from June 1998 to present, EnterNet, Inc., a wholesale distributor of vitamins through the Internet from March 2000 to July 2001, and Canadian Metals Exploration Ltd., formally known as Bren-Mar Minerals, Ltd., a Canadian mineral resource development company from 1995 to June 2001. Mr. Campbell is also the president and sole director of Aswan Investments, Inc., Cairo Acquisitions, Inc. and Alexandria Holdings, Inc., three shell companies that are fully reporting under the Exchange Act of 1934.

#### Compliance with Section 16(a) of the Exchange Act

Based solely upon a review of Forms 3, 4 and 5 furnished to the Company, the Company is aware of three individuals or entities who during the transitional period ended December 31, 2001 were directors, officers, or beneficial owners of more than ten percent of the common stock of the Company, and who failed to file, on a timely basis, reports required by Section 16(a) of the Securities Exchange Act of 1934.

Dr. Aydin Dogan - Dr. Dogan was appointed to the board of directors in 1998. He resigned from the board of directors and as an officer on December 18, 2000. Further, Dr. Dogan owns 8,245,000 or 18.96% of the Company's common stock. Dr. Dogan failed to file a Form 3 in a timely manner. Dr. Dogan further failed to file a Form 5 for the year ended December 31, 2001. Dr. Robert Ersek - Dr. Ersek and his wholly owned corporation, Graeco II, Ltd. own 8,810,000 or 20.26% of the Company's common stock. Dr. Ersek failed to file a Form 3 in a timely manner. Dr. Ersek further failed to file a Form 5 for the year ended December 31, 2001.

Art Beisang - Mr. Beisang and his wholly owned corporation, AAB Corporation own 8,750,000 or 20.12%. Dr. Ersek failed to file a Form 3 in a timely manner. Dr. Ersek further failed to file a Form 5 for the year ended December 31, 2001.

Edgar Filing: NOVAMED INC - Form 10KSB

ITEM 10. EXECUTIVE COMPENSATION

The following table provides summary information for the years 2001, 2000 and 1999 concerning cash and noncash compensation paid or accrued by the Company to or on behalf of president and the only other employee to receive compensation in excess of \$100,000.

SUMMARY COMPENSATION TABLE

Name and Principal	Year	Annual Compensation				Restricted Stock Award(s)	Long Term Compensation Awards		All
		Salary	Bonus	Other Annual Compensation	Securities Underlying Options/ SARs (#)		LTI Payouts	Compe	
Position	(\$)	(\$)	(\$)	(\$)	(\$)	SARs (#)	(\$)	(	
Ruairidh	2001	24,000	-	-	-	-	-	-	
Campbell	2000	67,000	-	-	2,000,000	30,0001	-	-	
President	1999	120,000	-	-	-	55,0002	-	-	
Dr. Aydin, President of NovaMedical Products GmbH	2001 1999 1998	- 80,000 160-000	- - -	- - -	- - -	- 20,0003 100,0004	- - -	- - -	

Compensation of Directors

The Company's director is not currently compensated for their services as directors of the Company.

1 Shares under option at \$0.45 a share expired as of March 2001 2 Shares under option at \$1.30 a share expired as of March 2001 3 Shares under option at \$0.45 a share expired as of March 2001 4 Shares under option at \$1.30 a share expired as of March 2001

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the beneficial ownership of the stock of the Company as of April 15, 2002, by each shareholder who is known by the Company to beneficially own more than 5% of the outstanding common stock, by each director, and by all executive officers and directors as a group.

Title of Class	Name and Address of Beneficial Ownership	Amount and nature of Beneficial Ownership	Perce
----------------	--	---	-------



## Edgar Filing: NOVAMED INC - Form 10KSB

Common Stock	Ruairidh Campbell 600 Westwood Terrace Austin, Texas 78746	2,150,000
Common Stock	Dr. Aydin Dogan 3 Heinestrasse D-40789 Monheim, Germany	8,245,000
Common Stock	Graeco II, Ltd. 630 West 34th Street #201 Austin, Texas 78705	8,810,000
Common Stock	AAB Corporation 5009 White Bear Lake Minnesota 55110	8,750,000
Common Stock	All Executive Officers and Directors as a Group	2,150,000

\* Dr. Robert Ersek is the legal and beneficial owner of Graeco II, Ltd. \*\* Art Beisang is the legal and beneficial owner of AAB Corporation.

### ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

On December 31, 2000, the Company issued 6,400,000 shares of common stock to Dr. Aydin Dogan pursuant to an agreement for accord and satisfaction, for consulting services rendered in connection with his management of Novamedical Products GmbH and loans provided to the Company, pursuant to the exemptions provided by Regulation S of the Securities Act in a private transaction that did not include a public offering. Amounts due to Dr. Dogan under a consulting agreement with Novamedical Products GmbH and loans made to the Company were settled. The Company chose to issue the shares to Dr. Dogan in order satisfy his claims for compensation for services and loans made. Further, the Company canceled a promissory note due to the Company by Dr. Dogan.

On December 31, 2000, the Company issued 1,020,000 shares of common stock to Dr. Aydin Dogan for debt settlement services in connection with the sale of Novamedical Products GmbH, rendered pursuant to the exemptions provided by Regulation S of the Securities Act in a private transaction that did not include a public offering. The share issuance to Dr. Dogan was part of a stock purchase and sale agreement pursuant to the terms of which the Company was to issue 1,350,000 shares to be used to settle the claims of creditors of Novamedical Products GmbH. The Company issued 330,000 shares to creditors directly and 1,022,000 shares to Dr. Dogan for his use in settling creditors.

On December 29, 2000, the Company issued 8,750,000 shares of common stock to AAB Corporation for inducement to enter into a new license agreement with the Company, settlement of royalty debts and pre-payment on royalties, pursuant to section 4(2) of the Securities Act in a private transaction that did not include a public offering. The share issuance to AAB Corporation induced it to enter into a new licence agreement with the Company executed on even date that enables the Company to utilize certain patented technology in the manufacture of its products.

On December 29, 2000, the Company issued 8,750,000 shares of common stock to

## Edgar Filing: NOVAMED INC - Form 10KSB

Greaco II, Ltd. for inducement to enter into a new license agreement with the Company, settlement of royalty debts and pre-payment on royalties, pursuant to section 4(2) of the Securities Act in a private transaction that did not include a public offering. The share issuance to Greaco II, Ltd. induced it to enter into a new licence agreement with the Company executed on even date that enables the Company to utilize certain patented technology in the manufacture of its products.

On December 26, 2000, the Company issued 2,000,000 shares of common stock to Ruairidh Campbell in consideration for services rendered in 2000 as president of the Company, pursuant to section 4(2) of the Securities Act in a private transaction that did not include a public offering. The Company issued the shares to Mr. Campbell as part of a plan to reduce or eliminate amounts due to creditors. Mr. Campbell's services had not been adequately compensated and therefore the decision was taken to settle all obligations to Mr. Campbell as of year end 2000.

### ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K

- (a) Exhibits. Exhibits required to be attached by Item 601 of Regulation S-B are listed in the Index to Exhibits beginning on page 16 of this Form 10-KSB, which is incorporated herein by reference.
- (b) Reports on Form 8-K. The Company filed no Form 8K's during the last quarter of the period covered by this Form 10-KSB.

[THIS SPACE HAS BEEN LEFT BLANK INTENTIONALLY]

### SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, this 15th day of April, 2002

Edgar Filing: NOVAMED INC - Form 10KSB

NovaMed, Inc.

/s/ Ruairidh Campbell

-----  
Ruairidh Campbell, President/CFO and Director

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Ruairidh Campbell	President and Director	April 15, 2002
----- Ruairidh Campbell		

15

INDEX TO EXHIBITS

EXHIBIT NO.	PAGE NO.	DESCRIPTION
3(i)	*	Articles of Incorporation of the Company formally known as Conceptua Technologies, Inc. a Nevada corporation dated November 26, 1996 (incorporated herein by reference from Exhibit No. 2(i) to the Compa 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
3(ii)		* Bylaws of the Company adopted on November 12, 1996 (incorporated herein by reference from Exhibit 2(iv) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).

## Edgar Filing: NOVAMED INC - Form 10KSB

- 3(iii) \* Certificate of Amendment of the Articles of Incorporation of the Company on August 29, 1997 effecting a 1-for-14 reverse split and rounding of fractional share to one whole share (incorporated herein by reference from Exhibit 2(ii) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 3(iv) \* Certificate of Amendment of the Articles of Incorporation of the Company changing the name from Conceptual Technologies, Inc. to NovaMed, Inc. (incorporated herein by reference from Exhibit 2(iii) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- Material Contracts
- 10(i) \* Stock Purchase and Sale Agreement between Conceptual Technologies, Inc. and NovaMed Medical Products Incorporated, dated February 25, 1998, pursuant to which the Company acquired all its current operations (incorporated herein by reference from Exhibit 6(i) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 10(ii) \* Letter Agreement-Strategic Alliance between the Company and Inamed, dated March 25, 1999 for the sale of the Company's NOVAGOLD(TM) implants internationally and the sale of the NOVASALINE(TM) pre-filled implant (incorporated herein by reference from Exhibit 6(ii) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 10(iii) \* Second Amendment to the Lease Agreement between the Company and Michael Realty Company dated October 8, 1998 for the lease of the Company's office and manufacturing facilities in Minnesota (incorporated herein by reference from Exhibit 6(iii) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 16
- 10(iv) \* The Company's Stock Option Plan dated March 19, 1999, reserving a maximum of 500,000 shares of common stock to provide incentives to officers, directors and key employees (incorporated herein by reference from Exhibit 6(iv) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 10(v) \* Stock Option Agreement between the Company and Ruairidh Campbell dated March 19, 1999, granting him the option to purchase up to 55,000 shares of common stock of the Company for \$1.30 a share (incorporated herein by reference from Exhibit 6(v) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 10(vi) \* Stock Option Agreement between the Company and Dr. Howard Bellin dated March 19, 1999, granting him the option to purchase up to 35,000 shares of common stock of the Company for \$1.30 a share (incorporated herein by reference from Exhibit 6(vi) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).

## Edgar Filing: NOVAMED INC - Form 10KSB

- 10(vii) \* Correspondence between the Company and IKB Deutsche Industrie Bank dated June 10, 1999 discussing various terms of loan to establish production facilities in Duisberg, Germany (incorporated herein by reference from Exhibit 6(v) of the Company's Form 10SB12G/A as filed with the Securities and Exchange Commission on November 29, 1999).
- 10(viii) \* The Company's Stock Option Plan dated March 2, 2000, reserving a maximum of 1,315,000 shares of common stock to provide incentives to officers and key employees (incorporated herein by reference to the Company's registration statement filed with the Securities and Exchange Commission on March 2, 2000).
- 10(ix) \* Stock Option Agreement between the Company and Dr. Aydin Dogan, dated February 29, 2000, granting him the option to purchase 20,000 shares of the Company for \$0.45 a share (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).
- 10(x) \* Stock Option Agreement between the Company and Dr. Howard Bellin, dated February 29, 2000, granting him the option to purchase 20,000 shares of the Company for \$0.45 a share (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).
- 10(xi) \* Stock Option Agreement between the Company and Ruairidh Campbell, dated February 29, 2000, granting him the option to purchase 30,000 shares of the Company for \$0.45 a share (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).
- 17
- 10(xii) \* Stock Option Agreement between the Company and Dr. Franz Schain, dated February 29, 2000, granting him the option to purchase 300,000 shares of the Company for \$0.45 a share (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).
- 10(xiii) \* License Agreement between the Company and AAB Corp. Ltd. and Greaco Ltd. ("Inventors") dated December 27, 2000 for the use of patented technology in the manufacture of the Company's products (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).
- 10(xiv) \* Agreement for the Issuance, Sale and Purchase of NovaMed Common Stock between the Company and AAB Corp. and Greaco II, Ltd. dated December 27, 2001 for the issuance of a combined total of 17,500,000 shares to them as a means to induce them to enter into a new license agreement, set forth in the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001, and to be paid in full by the Company, less amounts owed on royalties and pre-pay royalty payments (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).
- 10(xv) \* Agreement for Accord and Satisfaction between the Company and Dr. Aydin Dogan dated December 31, 2000 for the issuance of 6,400,000 shares of the Company to him in full satisfaction of the obligations Dr. Dogan had against the Company and settle obligations

## Edgar Filing: NOVAMED INC - Form 10KSB

Company had against Dr. Dogan pursuant to a promissory note (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).

10(xvi)

\*

Stock Purchase and Sale Agreement between the Company and Dr. Aydin Dogan dated December 31, 2000 to effect the sale of Novamedical Products GmbH to Dr. Dogan, the terms of which included the issuance of 1,350 shares of common stock to settle creditors of Novamedical Products GmbH (incorporated herein by reference to the Company's Form 10-KSB filed with the Securities and Exchange Commission on May 21, 2001).

10(xvii)

\*

Stock Sale Agreement between the Company and John Olson dated March 17, 2001 to effect the sale of the Company's interest in a subsidiary (incorporated herein by reference to the Company's Form 8-K filed with the Securities and Exchange Commission on March 4, 2002).

\* Incorporated by reference from previous filings of the Company.